2024-13-003 + 2018-04-013 - VIP -02 - Voxel Imaging Positron emission tomography detector

VIP -02

2024-13-003 + 2018-04-013

PET scanner with 3D high granular spatial resolution plus high energy resolution. Reduce the radiation dose for the patient by a factor of 10 and detection position of the photon is measured precisely, with an error of 300 μm

Social and environmental advantages for public health system, reducing PET scan time per patient, then reduction of energy consumption and early detection of health diseases.

Reduction of EU cancer mortality by early tumor detection.

Cancer alone claimed the lives of approximately 10 million people globally, according to the World Health Organization (WHO). Both the developed and developing worlds are expected to see a rise in cancer cases. It is expected that one out of every nine Indians will develop cancer at some point in their lives. Heart disease is the leading cause of death worldwide, accounting for 16 percent of all deaths. Early detection increases the odds of survival dramatically, and nuclear medicine equipment plays a critical part in this. This has led to a rapid rise in the adoption of nuclear medicine equipment. Furthermore, the rise in lifestyle disorders such as cardiovascular disease and cancer has led in an increase in the target patient population and a demand for early detection and treatment by hospitals around the world. As a result of the increase in lifestyle illnesses, governmental and private entities have boosted their investment in Research Centers, making this area the fastest expanding with a CAGR of 4.8 percent. The nuclear medicine equipment market opportunities are on the rise.

3400000000

496543095.7375973

19861723.82950389

To create a spin-off offering PET/SPECT detectors. Our Voxel Imaging PET technology revolutionizes real-time brain metabolism visualization with unmatched time resolution, capturing metabolic activity like never before. Key innovations include Compton imaging detectors that significantly enhance spatial and energy resolution, and the integration of positron-emitting isotopes for rapid and precise localization of decay origins. This cutting-edge combination allows for earlier, more accurate disease detection. B2B model, producing and selling high-precision sensor modules while capturing margins through hardware sales, specifically targeting PET and SPECT manufacturers. Additionally, we provide customer support and software licensing. The global Nuclear Medicine Equipment Market size was valued at $2.5 billion in 2020, and is projected to reach $3.4 billion by 2030, growing at a CAGR of 3.2% from 2021 to 2030.

The increasing frequency of cancer, cardiovascular and neurology illnesess, as well as the growing need for image-guided operations and diagnostics is rising SPECT and PET applications. Nuclear medicine's success may be attributed to the fact that it provides a unique and non-invasive access to information at the molecular and cellular levels that other imaging technologies cannot imitate. The introduction of SPECT detectors based on cadmium zinc telluride has aided in the simultaneous viewing of physiological and anatomical systems. Furthermore, rising demand for Alzheimer's and Parkinson's disease treatment and diagnostics in China and India is fuelling the Asia Pacific sales of nuclear medicine equipment.

Our targets are PET and SPECT manufacturers like GE Healthcare, Siemens Healthineers, and smaller producers, focusing on the growing demand for high-precision imaging devices used in hospitals and research centers

PET real-time MVP construction

10M€

EIC project proposal; New patent application; Spin-off's creation

High image resolution enabling real time imaging diagnosis for early cancer detection, among other health diseases (Parkinson, Alzheimer, etc).

R&D development is expensiv; product certification needs; few sensing material providers

PET brain detector PoC validation with radiotracers. SPECT preclinical detector pilot development with a hospital + interaction with early adopters (1 year). Spin-off incorporation. Preclinical Testing (1-2 years). Regulatory Approval (2-4 years). Manufacturing Scale-Up (6 months-1 year).

2 patent families granted in the main geographic areas (EU, USA, CN, JP)

VIP 1 patent ready for licensing (TRL 5 ); VIP patent 2 valorization pending (TRL2)

Preclinical Testing and Validation. Duration: 1 to 2 years. Perform preclinical testing using animal models or in lab environments. Ensure the detector meets performance, safety, and reliability standards. Refine the product based on testing feedback. Regulatory Approval. Duration: 2 to 4 years. Prepare and submit regulatory documents for FDA approval (Class II or III), CE marking, or other regional regulations. Conduct clinical trials in hospitals to demonstrate efficacy and safety in real-world medical scenarios. Navigate premarket approval (PMA) process for new technologies or devices.

Patents: WO2010034619A1 ; WO2018019941A1 - Date: Jul 1st, 2018 Status: Granted URL: https://patents.google.com/patent/WO2010034619A1/en ; https://patents.google.com/patent/WO2018019941A1/en

Main advantages: • Has an excellent energy resolution of 1-2% at an energy of 511 keV, thus reducing the scatter fraction from 40% to 4% and hence the noise of the reconstructed PET image get reduced. • Both features, small Parallax and small scattered fraction implies the ability to obtain sharp images with excellent contrast allowing the detection of cancerous lesion as small as 2mm, in diameter in a signal to background ratio of 3:1. • Has adequate detection efficiency for 511 keV photons thanks to the high CdTe stopping power and seamless geometry. Thus, reducing the overall dose and the duration of the scan. • It is an excellent detector module to be used for Single Photon Emission Tomography (SPECT) scanner. One can also construct large Field Of View (FOV) Compton Camera scanner.